Three bovine veterinarians had undetected H5N1 avian influenza infections despite no apparent contact with infected cows, ...
Investing.com -- Morgan Stanley expects the FDA to approve Gilead Sciences (NASDAQ: GILD )' Lenacapavir (LEN) for HIV ...
Ligand originated, structured, and invested $50 million and led a syndicate of co-investors who invested $25 million in ...
The discussion ended with a bold call to action for businesses, healthcare providers, and policymakers: health equity must be a priority—not just ethically, but economically. As Burgess put it: “This ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...
The EMA is set to perform accelerated reviews of Gilead Sciences’ applications for its twice-yearly injectable for HIV ...
Gilead (GILD) announced that the European Medicines Agency has validated for parallel accelerated review the company’s marketing authorization ...
A common CV risk factor calculator for patients with HIV underestimates risk for Black patients and women, while risk for ...
We recently published a list of Renaissance Technologies Portfolio: Top 10 Stock Picks. In this article, we are going to take ...
Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a ...
MarketBeat on MSN3d
Gilead Sciences: 4 Reasons This Stock Has Much More To RiseCompanyOverview|NASDAQ:GILD] Gilead Sciences Inc. (NASDAQ: GILD) stock surged to a new 52-week high at $106.69 recently on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback